The manzamines represent a class of marine natural products that show considerable promise in the control of malaria but generate GI distress in rodents when administered orally in high doses. In an effort to generate manzamine prodrugs with improved antimalarial activity and reduced GI toxicity, we prepared acetylated 8-hydroxymanzamine A analogues including 8-acetoxymanzamine A (3) and 8,12-diacetoxymanzamine A (4), and 8-methoxymanzamine A (5) beginning with 8-hydroxymanzamine A (2). The semisynthetic analogues were assayed for antimalarial and antimicrobial activities, cytotoxicity, and biological and chemical stability. Due to gradual hydrolysis of the ester group, application of monoacetate 3 as an antimalarial prodrug was investigated. The in vitro and in vivo bioassays show that acetylated analogues exhibit significant antimalarial activity (IC50( 3) 9.6-30 ng/mL), which are comparable to the parent molecule; however the monoaceate 3 was shown to actually produce higher toxicity at 30 mg/kg when administered orally.
The manzamines represent a class of marine natural products that show considerable promise in the control of n class="Disease">malaria but generate GI distress in rodents when administered orally in high doses. In an effort to generate manzamine prodrugs with improved antimalarial activity and reduced GI toxicity, we prepared acetylated 8-hydroxymanzamine A analogues including 8-acetoxymanzamine A (3) and 8,12-diacetoxymanzamine A (4), and 8-methoxymanzamine A (5) beginning with 8-hydroxymanzamine A (2). The semisynthetic analogues were assayed for antimalarial and antimicrobial activities, cytotoxicity, and biological and chemical stability. Due to gradual hydrolysis of the ester group, application of monoacetate 3 as an antimalarial prodrug was investigated. The in vitro and in vivo bioassays show that acetylated analogues exhibit significant antimalarial activity (IC50( 3) 9.6-30 ng/mL), which are comparable to the parent molecule; however the monoaceate 3 was shown to actually produce higher toxicity at 30 mg/kg when administered orally.
Authors: Mark Hamann; Diana Alonso; Ester Martín-Aparicio; Ana Fuertes; M José Pérez-Puerto; Ana Castro; Susana Morales; María Luisa Navarro; María Del Monte-Millán; Miguel Medina; Hari Pennaka; Akula Balaiah; Jiangnan Peng; Jennifer Cook; Subagus Wahyuono; Ana Martínez Journal: J Nat Prod Date: 2007-08-21 Impact factor: 4.050
Authors: Jiangnan Peng; Sucheta Kudrimoti; Sivaprakasam Prasanna; Srinivas Odde; Robert J Doerksen; Hari K Pennaka; Yeun-Mun Choo; Karumanchi V Rao; Babu L Tekwani; Vamsi Madgula; Shabana I Khan; Bin Wang; Alejandro M S Mayer; Melissa R Jacob; Lan Chun Tu; Jürg Gertsch; Mark T Hamann Journal: J Med Chem Date: 2010-01-14 Impact factor: 7.446
Authors: Andre G Tempone; Pauline Pieper; Samanta E T Borborema; Fernanda Thevenard; Joao Henrique G Lago; Simon L Croft; Edward A Anderson Journal: Nat Prod Rep Date: 2021-12-15 Impact factor: 13.423
Authors: María Álvarez-Bardón; Yolanda Pérez-Pertejo; César Ordóñez; Daniel Sepúlveda-Crespo; Nestor M Carballeira; Babu L Tekwani; Sankaranarayanan Murugesan; Maria Martinez-Valladares; Carlos García-Estrada; Rosa M Reguera; Rafael Balaña-Fouce Journal: Mar Drugs Date: 2020-03-31 Impact factor: 5.118
Authors: Alejandro M S Mayer; Mary L Hall; Joseph Lach; Jonathan Clifford; Kevin Chandrasena; Caitlin Canton; Maria Kontoyianni; Yeun-Mun Choo; Dev Karan; Mark T Hamann Journal: Mar Drugs Date: 2021-09-07 Impact factor: 5.118